
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Characteristics and natural history of early-stage cardiac transthyretin amyloidosis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="ABCB780D925FBE433D780D002CB12D0E.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="ehj">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9279112/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="European Heart Journal">
<meta name="citation_title" content="Characteristics and natural history of early-stage cardiac transthyretin amyloidosis">
<meta name="citation_author" content="Steven Law">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Melanie Bezard">
<meta name="citation_author_institution" content="Referral Center for Cardiac Amyloidosis, Department of Cardiology, Mondor Amyloidosis Network, GRC Amyloid Research Institute, Clinical Investigation Center 006, DHU A-TVB INSERM U955 all at CHU Henri Mondor, UPEC, Créteil, France">
<meta name="citation_author" content="Aviva Petrie">
<meta name="citation_author_institution" content="Biostatistics Unit, UCL Eastman Dental Institute, University College London, London, UK">
<meta name="citation_author" content="Liza Chacko">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Oliver C Cohen">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Sriram Ravichandran">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Olabisi Ogunbiyi">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Mounira Kharoubi">
<meta name="citation_author_institution" content="Biostatistics Unit, UCL Eastman Dental Institute, University College London, London, UK">
<meta name="citation_author" content="Sashiananthan Ganeshananthan">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Sharmananthan Ganeshananthan">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Janet A Gilbertson">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Dorota Rowczenio">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Ashutosh Wechalekar">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Ana Martinez-Naharro">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Helen J Lachmann">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Carol J Whelan">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="David F Hutt">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Philip N Hawkins">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Thibaud Damy">
<meta name="citation_author_institution" content="Referral Center for Cardiac Amyloidosis, Department of Cardiology, Mondor Amyloidosis Network, GRC Amyloid Research Institute, Clinical Investigation Center 006, DHU A-TVB INSERM U955 all at CHU Henri Mondor, UPEC, Créteil, France">
<meta name="citation_author" content="Marianna Fontana">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_author" content="Julian D Gillmore">
<meta name="citation_author_institution" content="National Amyloidosis Centre, Division of Medicine, University College London, London, UK">
<meta name="citation_publication_date" content="2022 May 24">
<meta name="citation_volume" content="43">
<meta name="citation_issue" content="27">
<meta name="citation_firstpage" content="2622">
<meta name="citation_doi" content="10.1093/eurheartj/ehac259">
<meta name="citation_pmid" content="35608040">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9279112/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9279112/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9279112/pdf/ehac259.pdf">
<meta name="description" content="Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly diagnosed at an early stage of the disease natural history, defined as National Amyloidosis Centre (NAC) ATTR Stage I. The natural history of early-stage ATTR-CM remains poorly ...">
<meta name="og:title" content="Characteristics and natural history of early-stage cardiac transthyretin amyloidosis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly diagnosed at an early stage of the disease natural history, defined as National Amyloidosis Centre (NAC) ATTR Stage I. The natural history of early-stage ATTR-CM remains poorly ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9279112/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="9279112">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1093/eurheartj/ehac259"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/ehac259.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC9279112%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/9279112/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/9279112/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC9279112/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-ehj.png" alt="European Heart Journal logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to European Heart Journal" title="Link to European Heart Journal" shape="default" href="http://eurheartj.oxfordjournals.org/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Eur Heart J</button></div>. 2022 May 24;43(27):2622–2632. doi: <a href="https://doi.org/10.1093/eurheartj/ehac259" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1093/eurheartj/ehac259</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Eur%20Heart%20J%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Eur%20Heart%20J%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Eur%20Heart%20J%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Eur%20Heart%20J%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Characteristics and natural history of early-stage cardiac transthyretin amyloidosis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Law%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Steven Law</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Steven Law</span></h3>
<div class="p">
<sup>1</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Law%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Steven Law</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bezard%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Melanie Bezard</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Melanie Bezard</span></h3>
<div class="p">
<sup>2</sup>
Referral Center for Cardiac Amyloidosis, Department of Cardiology, Mondor Amyloidosis Network, GRC Amyloid Research Institute, Clinical Investigation Center 006, DHU A-TVB INSERM U955 all at CHU Henri Mondor, UPEC, Créteil, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bezard%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Melanie Bezard</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Petrie%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Aviva Petrie</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Aviva Petrie</span></h3>
<div class="p">
<sup>3</sup>
Biostatistics Unit, UCL Eastman Dental Institute, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Petrie%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Aviva Petrie</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chacko%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Liza Chacko</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Liza Chacko</span></h3>
<div class="p">
<sup>4</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chacko%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Liza Chacko</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cohen%20OC%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Oliver C Cohen</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Oliver C Cohen</span></h3>
<div class="p">
<sup>5</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cohen%20OC%22%5BAuthor%5D" class="usa-link"><span class="name western">Oliver C Cohen</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ravichandran%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Sriram Ravichandran</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Sriram Ravichandran</span></h3>
<div class="p">
<sup>6</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ravichandran%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sriram Ravichandran</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ogunbiyi%20O%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Olabisi Ogunbiyi</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Olabisi Ogunbiyi</span></h3>
<div class="p">
<sup>7</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ogunbiyi%20O%22%5BAuthor%5D" class="usa-link"><span class="name western">Olabisi Ogunbiyi</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kharoubi%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Mounira Kharoubi</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Mounira Kharoubi</span></h3>
<div class="p">
<sup>8</sup>
Biostatistics Unit, UCL Eastman Dental Institute, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kharoubi%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mounira Kharoubi</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ganeshananthan%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Sashiananthan Ganeshananthan</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Sashiananthan Ganeshananthan</span></h3>
<div class="p">
<sup>9</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ganeshananthan%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sashiananthan Ganeshananthan</span></a>
</div>
</div>
<sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ganeshananthan%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Sharmananthan Ganeshananthan</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Sharmananthan Ganeshananthan</span></h3>
<div class="p">
<sup>10</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ganeshananthan%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sharmananthan Ganeshananthan</span></a>
</div>
</div>
<sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gilbertson%20JA%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Janet A Gilbertson</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Janet A Gilbertson</span></h3>
<div class="p">
<sup>11</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gilbertson%20JA%22%5BAuthor%5D" class="usa-link"><span class="name western">Janet A Gilbertson</span></a>
</div>
</div>
<sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rowczenio%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Dorota Rowczenio</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Dorota Rowczenio</span></h3>
<div class="p">
<sup>12</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rowczenio%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dorota Rowczenio</span></a>
</div>
</div>
<sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wechalekar%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Ashutosh Wechalekar</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Ashutosh Wechalekar</span></h3>
<div class="p">
<sup>13</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wechalekar%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ashutosh Wechalekar</span></a>
</div>
</div>
<sup>13</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Martinez-Naharro%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Ana Martinez-Naharro</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Ana Martinez-Naharro</span></h3>
<div class="p">
<sup>14</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Martinez-Naharro%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ana Martinez-Naharro</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lachmann%20HJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Helen J Lachmann</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Helen J Lachmann</span></h3>
<div class="p">
<sup>15</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lachmann%20HJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Helen J Lachmann</span></a>
</div>
</div>
<sup>15</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Whelan%20CJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Carol J Whelan</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Carol J Whelan</span></h3>
<div class="p">
<sup>16</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Whelan%20CJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Carol J Whelan</span></a>
</div>
</div>
<sup>16</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hutt%20DF%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">David F Hutt</span></a><div hidden="hidden" id="id17">
<h3><span class="name western">David F Hutt</span></h3>
<div class="p">
<sup>17</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hutt%20DF%22%5BAuthor%5D" class="usa-link"><span class="name western">David F Hutt</span></a>
</div>
</div>
<sup>17</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hawkins%20PN%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">Philip N Hawkins</span></a><div hidden="hidden" id="id18">
<h3><span class="name western">Philip N Hawkins</span></h3>
<div class="p">
<sup>18</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hawkins%20PN%22%5BAuthor%5D" class="usa-link"><span class="name western">Philip N Hawkins</span></a>
</div>
</div>
<sup>18</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Damy%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id19"><span class="name western">Thibaud Damy</span></a><div hidden="hidden" id="id19">
<h3><span class="name western">Thibaud Damy</span></h3>
<div class="p">
<sup>19</sup>
Referral Center for Cardiac Amyloidosis, Department of Cardiology, Mondor Amyloidosis Network, GRC Amyloid Research Institute, Clinical Investigation Center 006, DHU A-TVB INSERM U955 all at CHU Henri Mondor, UPEC, Créteil, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Damy%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Thibaud Damy</span></a>
</div>
</div>
<sup>19</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fontana%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id20"><span class="name western">Marianna Fontana</span></a><div hidden="hidden" id="id20">
<h3><span class="name western">Marianna Fontana</span></h3>
<div class="p">
<sup>20</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fontana%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Marianna Fontana</span></a>
</div>
</div>
<sup>20,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gillmore%20JD%22%5BAuthor%5D" class="usa-link" aria-describedby="id21"><span class="name western">Julian D Gillmore</span></a><div hidden="hidden" id="id21">
<h3><span class="name western">Julian D Gillmore</span></h3>
<div class="p">
<sup>21</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gillmore%20JD%22%5BAuthor%5D" class="usa-link"><span class="name western">Julian D Gillmore</span></a>
</div>
</div>
<sup>21,</sup><sup>✉,</sup><sup>2</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>1</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff2">
<sup>2</sup>
Referral Center for Cardiac Amyloidosis, Department of Cardiology, Mondor Amyloidosis Network, GRC Amyloid Research Institute, Clinical Investigation Center 006, DHU A-TVB INSERM U955 all at CHU Henri Mondor, UPEC, Créteil, France</div>
<div id="aff3">
<sup>3</sup>
Biostatistics Unit, UCL Eastman Dental Institute, University College London, London, UK</div>
<div id="aff4">
<sup>4</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff5">
<sup>5</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff6">
<sup>6</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff7">
<sup>7</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff8">
<sup>8</sup>
Biostatistics Unit, UCL Eastman Dental Institute, University College London, London, UK</div>
<div id="aff9">
<sup>9</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff10">
<sup>10</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff11">
<sup>11</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff12">
<sup>12</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff13">
<sup>13</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff14">
<sup>14</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff15">
<sup>15</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff16">
<sup>16</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff17">
<sup>17</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff18">
<sup>18</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff19">
<sup>19</sup>
Referral Center for Cardiac Amyloidosis, Department of Cardiology, Mondor Amyloidosis Network, GRC Amyloid Research Institute, Clinical Investigation Center 006, DHU A-TVB INSERM U955 all at CHU Henri Mondor, UPEC, Créteil, France</div>
<div id="aff20">
<sup>20</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div id="aff21">
<sup>21</sup>
National Amyloidosis Centre, Division of Medicine, University College London, London, UK</div>
<div class="author-notes p">
<div class="fn" id="ehac259-cor1">
<sup>✉</sup><p class="display-inline">Corresponding author. Tel: +44 20 74332816, Fax: +44 20 74332844, Email: <span>j.gillmore@ucl.ac.uk</span></p>
</div>
<div class="fn" id="ehac259-FM1">
<sup>2</sup><p class="display-inline">Marianna Fontana and Julian D. Gillmore joint last authors of this work.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2021 Sep 10; Revised 2022 Apr 18; Accepted 2022 May 6; Collection date 2022 Jul 14.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology.</div>
<p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<a href="https://creativecommons.org/licenses/by-nc/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by-nc/4.0/</a>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC9279112  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35608040/" class="usa-link">35608040</a>
</div>
<div class="ra xbox p" role="complementary" aria-label="Related or updated information about this article"><div>See "<a href="https://pubmed.ncbi.nlm.nih.gov/35639645/" class="usa-link">Early-stage amyloid transthyretin cardiomyopathy: uncertainties and opportunities.</a>" with doi: 10.1093/eurheartj/ehac261.</div></div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="s1"><h3 class="pmc_sec_title">Aims</h3>
<p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly diagnosed at an early stage of the disease natural history, defined as National Amyloidosis Centre (NAC) ATTR Stage I. The natural history of early-stage ATTR-CM remains poorly characterized.</p></section><section id="s2"><h3 class="pmc_sec_title">Methods and results</h3>
<p>A retrospective multi-centre observational study of 879 patients with ATTR-CM, either wild-type TTR genotype or carrying the p.V142I TTR variant, and NAC ATTR Stage I biomarkers at the time of diagnosis who did not receive disease-modifying therapy for amyloidosis. Disease characteristics at diagnosis that were independently associated with mortality by Cox regression analysis were N-terminal pro-B-type natriuretic peptide (NT-proBNP), TTR genotype, and troponin T. Patients were categorized into NAC ATTR Stage Ia, defined as a furosemide equivalent diuretic requirement of &lt;0.75 mg/kg and an NT-proBNP ≤500 ng/L or ≤1000 ng/L in the presence of atrial fibrillation, and NAC ATTR Stage Ib comprising all remaining Stage I patients. Median estimated survival among the 88% NAC ATTR Stage Ib patients was 75 (95% CI 57–93) months compared with &gt;100 months in the 12% with Stage Ia disease [hazard ratio for death 5.06 (95% confidence interval 1.23–20.87); <em>P</em> = 0.025] despite significant cardiovascular morbidity at the time of diagnosis which increased during follow-up, including among patients diagnosed in NAC ATTR Stage Ia. Estimated survival among UK NAC ATTR Stage Ia patients was comparable to UK general population controls (<em>P</em> = 0.297).</p></section><section id="s3"><h3 class="pmc_sec_title">Conclusion</h3>
<p>Patients with NAC ATTR Stage I ATTR-CM can be further stratified according to NT-proBNP concentration and diuretic requirement at diagnosis. Patients with Stage Ia ATTR-CM have significant cardiovascular morbidity despite good short- and mid-term survival.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> Amyloidosis, Amyloid, Transthyretin, TTR, Staging, Cardiomyopathy</p></section></section><section class="abstract" id="abstract2"><h2>Structured Graphical Abstract</h2>
<figure class="fig xbox font-sm" id="ehac259-ehac259ga1"><h3 class="obj_head">Structured Graphical Abstract.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9279112_ehac259ga1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0544/9279112/42b9d53f8244/ehac259ga1.jpg" loading="lazy" height="662" width="760" alt="Structured Graphical Abstract"></a></p>
<div class="p text-right font-secondary"><a href="figure/ehac259-ehac259ga1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Patients diagnosed with NAC ATTR Stage Ia amyloidosis have an estimated median survival in excess of 100 months in the absence of disease-modifying therapy despite significant cardiovascular morbidity which increases further during follow up.</p></figcaption></figure></section><hr class="headless">
<p>
<strong>See the editorial comment for this article ‘Early-stage amyloid transthyretin cardiomyopathy: uncertainties and opportunities’, by C. Rapezzi <em>et al</em>., <a href="https://doi.org/10.1093/eurheartj/ehac261" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1093/eurheartj/ehac261</a>.</strong>
</p>
<section id="ehac259-s1"><h2 class="pmc_sec_title">Introduction</h2>
<p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly diagnosed although only a small proportion of those individuals who have ATTR amyloid deposits in their hearts, according to prevalence estimates from post-mortem series, are ever diagnosed with cardiac amyloidosis in life.<sup><a href="#ehac259-B1" class="usa-link" aria-describedby="ehac259-B1">1–3</a></sup> Since the diagnosis of ATTR-CM is challenging and often missed, the true disease prevalence remains unknown.</p>
<p>The prognosis of patients who are diagnosed with ATTR-CM can be determined on the basis of National Amyloidosis Centre (NAC) ATTR Stage, which is calculated at the time of diagnosis according to N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration and estimated glomerular filtration rate (eGFR).<sup><a href="#ehac259-B4" class="usa-link" aria-describedby="ehac259-B4">4</a>,<a href="#ehac259-B5" class="usa-link" aria-describedby="ehac259-B5">5</a></sup> Initial reports indicated that ∼40% of patients were diagnosed in Stage I conferring a prognosis of &gt;5 years in the absence of disease-modifying therapy, with the remainder being Stage II or III associated with progressively worsening prognosis.<sup><a href="#ehac259-B4" class="usa-link" aria-describedby="ehac259-B4">4</a></sup> However, the recent improvement in diagnostic imaging techniques coupled with heightened awareness of ATTR-CM among cardiologists due to the availability of life-prolonging therapies, mean that &gt;50% of patients are now diagnosed with NAC Stage I ATTR-CM, a trend which is likely to increase further.<sup><a href="#ehac259-B6" class="usa-link" aria-describedby="ehac259-B6">6–13</a></sup></p>
<p>There are few data on the natural history of early-stage ATTR-CM. We sought to characterize the disease course and clinical outcome among patients diagnosed with early-stage ATTR-CM in the absence of disease-modifying therapy.</p></section><section id="ehac259-s2"><h2 class="pmc_sec_title">Methods</h2>
<section id="ehac259-s2.1"><h3 class="pmc_sec_title">Patients</h3>
<p>A retrospective analysis was conducted of all patients with ATTR-CM attending two large amyloidosis Centres, the UK NAC and the Amyloidosis Mondor Network, France between 27th August 2009 and 30th July 2020, who fulfilled all of the following inclusion criteria: wild-type <em>TTR</em> gene sequence or <em>TTR</em> mutation encoding the known pathogenic p.V142I variant; NAC ATTR Stage I biomarkers at the time of diagnosis; and absence of administration of disease-modifying therapy during clinical follow-up.<sup><a href="#ehac259-B4" class="usa-link" aria-describedby="ehac259-B4">4</a>,<a href="#ehac259-B7" class="usa-link" aria-describedby="ehac259-B7">7</a></sup> ATTR-CM was defined either by validated non-biopsy diagnostic criteria for ATTR-CM or by the presence of ATTR amyloid on histology from any biopsy site coupled with Perugini Grade ≥1 myocardial uptake on radionuclide scan. For clarity, validated non-biopsy criteria for ATTR-CM were defined as all of the following: echocardiogram or cardiac magnetic resonance suggestive of amyloid, Perugini Grade ≥2 radionuclide scan, and absence of a monoclonal protein by serum-free light chain assay and by serum and urine immunofixation.<sup><a href="#ehac259-B7" class="usa-link" aria-describedby="ehac259-B7">7</a></sup> NAC ATTR Stage I was defined as an NT-proBNP ≤ 3000 ng/L and eGFR ≥ 45 mL/min/1.73 m<sup>2</sup> at diagnosis. In order to focus on patients with predominant ATTR-CM, those with non-V122I-associated ATTRv amyloidosis were excluded due to the important but variable contributions of peripheral and autonomic neuropathy to both morbidity and mortality in those conditions.<sup><a href="#ehac259-B4" class="usa-link" aria-describedby="ehac259-B4">4</a></sup></p>
<p>Patients were systemically evaluated at diagnosis and on a 6–12 monthly basis thereafter as clinically indicated. Evaluations consisted of a full clinical history and examination alongside functional, biochemical, electrocardiography, and echocardiographic assessment. Hospitalization data were not reliably captured and therefore excluded from analyses. Throughout the study cardiovascular morbidity is defined by the presence of atrial fibrillation, cerebrovascular accident, permanent pacemaker, diuretic requirement, or New York Heart Association (NYHA) functional Class ≥II.</p>
<p>All patients were managed in accordance with the Declaration of Helsinki and provided informed consent for anonymous publication of their data. The study received IRB approval from the Royal Free Hospital Ethics Committee.</p></section><section id="ehac259-s2.2"><h3 class="pmc_sec_title">Biomarker analysis</h3>
<p>N-terminal pro-B-type natriuretic peptide was measured with an electrochemiluminescence sandwich immunoassay on the Elecsys system 2010 (Roche Diagnostics) and eGFR was calculated by standard Modification of Diet in Renal Disease study equation with correction for ethnicity. National Amyloidosis Centre ATTR disease stage was calculated according to previously published criteria.<sup><a href="#ehac259-B4" class="usa-link" aria-describedby="ehac259-B4">4</a></sup> High-sensitivity troponin T assay was performed with a second-generation assay after 16 December 2015, and before that, with a first-generation troponin T assay.</p></section><section id="ehac259-s2.3"><h3 class="pmc_sec_title">Radionuclide (<sup>99m</sup>Tc-DPD and <sup>99m</sup>Tc-HMDP) scintigraphy</h3>
<p>Patients were scanned after intravenous injection of ∼700 MBq of <sup>99m</sup>Tc-DPD providing an expected radiation dose of ∼4 mSv per patient. Whole-body planar and SPECT/CT images were acquired 3 h post-injection in all patients. Images were acquired using a low energy, high-resolution collimator, and a scan speed of 10 cm/min. Cardiac retention of all <sup>99m</sup>Tc-DPD scans was determined by two independent experienced readers according to the grading devised by Perugini <em>et al</em>. A heart to mediastinum (H:M) ratio of ≥1.21 on <sup>99m</sup>Tc-HMDP scintigraphy, previously reported to be equivalent to Perugini Grade ≥2,<sup><a href="#ehac259-B8" class="usa-link" aria-describedby="ehac259-B8">8</a>,<a href="#ehac259-B14" class="usa-link" aria-describedby="ehac259-B14">14</a></sup> is reported as Grade ≥2 throughout the manuscript.</p></section><section id="ehac259-s2.4"><h3 class="pmc_sec_title">Echocardiography</h3>
<p>Echocardiography was performed by three echocardiographers with extensive experience of cardiac amyloidosis on General Electric Vivid 7 machines using EchoPac software. All echocardiograms were read and reported by two independent experts in amyloid echocardiography.</p></section><section id="ehac259-s2.5"><h3 class="pmc_sec_title">Histology, immunohistochemistry, and proteomics</h3>
<p>All formalin-fixed paraffin-embedded biopsies were stained with Congo red dye and viewed under crossed polarized light according to the method of Puchtler <em>et al</em>.<sup><a href="#ehac259-B15" class="usa-link" aria-describedby="ehac259-B15">15</a></sup> The definitive amyloid fibril type was established by immunohistochemical staining of amyloid deposits using a panel of monospecific antibodies reactive with serum amyloid A protein, kappa and lambda immunoglobulin light chains, transthyretin, and where necessary, antibodies against apolipoprotein A-I, apolipoprotein A-IV, and fibrinogen Aα-chain, as previously described, and/or by microdissection of amyloid deposits and proteomic analysis, as previously described.<sup><a href="#ehac259-B16" class="usa-link" aria-describedby="ehac259-B16">16</a>,<a href="#ehac259-B17" class="usa-link" aria-describedby="ehac259-B17">17</a></sup></p></section><section id="ehac259-s2.6"><h3 class="pmc_sec_title">Genetic testing</h3>
<p>DNA was extracted from whole blood, amplified by polymerase-chain-reaction assay and the whole coding region of the transthyretin (<em>TTR</em>) gene was sequenced in all patients, as previously described.<sup><a href="#ehac259-B18" class="usa-link" aria-describedby="ehac259-B18">18</a></sup></p></section><section id="ehac259-s2.7"><h3 class="pmc_sec_title">Statistical methods</h3>
<p>The diagnosis was defined as the date of first review at a specialist amyloidosis centre, and follow-up was defined as the time from diagnosis to date of censoring or death. Patients were censored at the earliest of the following timepoints: 30 July 2020, date of commencement of disease-modifying therapy, enrolment into a clinical trial of disease-modifying therapy, or at 100 months of follow-up.</p>
<p>The association between patient characteristics at diagnosis and survival was explored by univariable Cox regression analyses, and subsequently by multivariable Cox regression analyses including variables known to be associated with survival in ATTR-CM according to the published literature.<sup><a href="#ehac259-B4" class="usa-link" aria-describedby="ehac259-B4">4</a>,<a href="#ehac259-B19" class="usa-link" aria-describedby="ehac259-B19">19</a>,<a href="#ehac259-B20" class="usa-link" aria-describedby="ehac259-B20">20</a></sup> Due to the independent prognostic power of NT-proBNP at diagnosis coupled with recently published literature demonstrating the independent association between loop diuretic equivalent dose requirement and survival in ATTR-CM,<sup><a href="#ehac259-B20" class="usa-link" aria-describedby="ehac259-B20">20</a></sup> the study population was stratified into two groups defined as: NAC ATTR Stage Ia—NT-proBNP ≤500 or ≤1000 ng/L in the presence of atrial fibrillation with a loop diuretic equivalent requirement of &lt;0.75 mg/kg, and NAC ATTR Stage Ib—NT-proBNP &gt;500 or &gt;1000 ng/L in the presence of atrial fibrillation or a loop diuretic requirement of ≥0.75 mg/kg. The NT-proBNP cut-offs were chosen to reflect the NT-proBNP eligibility criteria for recently conducted clinical trials of novel disease-modifying agents in ATTR-CM, some of which require the use of diuretics and acknowledge the effect of atrial fibrillation on NT-proBNP concentration independently of disease severity [ATTR-ACT (&gt;600 ng/L), ATTRibute-CM (&gt;300 ng/L), APOLLO-B (&gt;300 and &gt;600 ng/L in atrial fibrillation), HELIOS-B (&gt;300 and &gt;600 ng/L in atrial fibrillation), ION-CS2 (&gt;600 and &gt;1200 ng/L in atrial fibrillation), and ITL-2001-CL-001 (&gt;600 and &gt;1000 ng/L in atrial fibrillation)].<sup><a href="#ehac259-B10" class="usa-link" aria-describedby="ehac259-B10">10</a>,<a href="#ehac259-B21" class="usa-link" aria-describedby="ehac259-B21">21–23</a></sup> Loop diuretic doses were converted to a total daily furosemide equivalent dose; for example 1 mg bumetanide twice daily was converted to 80 mg as a total daily furosemide equivalent dose. A value of &lt;0.75 mg/kg was selected to identify patients with a relatively low diuretic requirement of ≤40 mg daily for patients &gt;53 and ≤80 kg in weight and ≤60 mg daily for patients of &gt;80 kg typically administered in mild heart failure or for non-heart failure indications. A single cut-off value was chosen for simplicity in order to maximize clinical utility of the staging system. Multivariable Cox regression analyses were subsequently repeated with replacement of NT-proBNP as a continuous variable and loop diuretic dosage by NAC ATTR Stages Ia and Ib as categorical variables. The proportional hazards assumption was checked and satisfied.</p>
<p>Cox regression analyses on the UK cohort alone could not be performed due to there being no deaths in Stage Ia patients from this subgroup; this prevented the creation of a multivariable Cox regression model on this group with subsequent external validation using the Amyloidosis Mondor Network cohort. We, therefore, divided the whole cohort into an 80% training group and 20% validation group to validate our multivariable Cox regression model containing NAC ATTR Stages Ia and Ib using the method reported by Royston.<sup><a href="#ehac259-B24" class="usa-link" aria-describedby="ehac259-B24">24</a></sup> We assessed the Cox proportional hazards regression model on the training data and calculated <em>R</em><sup>2</sup> for survival models, a measure of the explained variation in such models. The performance of <em>R</em><sup>2</sup> was evaluated using 1000 bootstrap samples on the validation data. The difference in <em>R</em><sup>2</sup> values between the training group and validation group was 0.047 [95% confidence interval (CI) −0.25 to 0.34] consistent with no real difference. In addition, a type of model calibration was performed by evaluation of <em>R</em><sup>2</sup>, allowing regression on the predicted index in the validation sample. The model was developed on the training sample and calibrated on the index in the validation sample using 1000 bootstrap samples. The calibration slope was 0.85 suggesting the model is adequately calibrated.</p>
<p>Patient characteristics at diagnosis stratified by NAC ATTR Stages Ia and Ib were compared by Kruskal–Wallis test (numerical variables) and χ<sup>2</sup> test (categorical variables). Patients were also stratified by Perugini grading of cardiac uptake on bone scintigraphy. Patient characteristics of those with NAC ATTR Stage Ia disease were subsequently stratified by presenting symptom into cardiovascular, defined as symptoms of cardiac failure, symptomatic arrhythmia, or cerebrovascular accident, and non-cardiovascular presentations. Kaplan–Meier (KM) survival analyses were performed to estimate median survival and illustrate survival percentages stratified by NAC ATTR Stage. Further KM survival analyses were performed on patients with NAC ATTR Stage Ia stratified by presenting symptom; survival is reported at 80 months of follow-up in these analyses as 100 months of follow-up was not reached in the cardiovascular presentation group. Log-rank tests were performed to compare patient survival between subgroups.</p>
<p>United Kingdom general population survival data were obtained from the Office of National Statistics. Each study patient was assigned an expected survival equivalent to the mean survival for a person of the same age and gender, from the year of diagnosis. These UK individuals were deemed to have died at their expected survival time if that time was &lt;100 months. Any UK individual whose expected survival time was equal to or &gt;100 months was taken as censored at 100 months. A KM survival curve was created for the expected survival times and this was superimposed on the KM survival curves. United Kingdom general population control groups were matched to the NAC ATTR Stage Ia group and the NAC ATTR Stage Ib separately to provide group-specific matching given the significant difference in patient age between Stages Ia and Ib. Survival comparisons with the matched UK population controls were restricted to the UK patient cohort due to differences in population life expectancy between France and the UK.</p>
<p>Data are presented as median (interquartile range) or number (percentage) unless otherwise stated. A <em>P</em>-value of &lt;0.05 was deemed significant. Summary statistics were obtained using SPSS v25 (IBM Corp, 2017) and all other analyses were performed using Stata v16 (Stata Corp, 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC.).</p></section></section><section id="ehac259-s3"><h2 class="pmc_sec_title">Results</h2>
<section id="ehac259-s3.1"><h3 class="pmc_sec_title">Patient characteristics</h3>
<p>There were 879 patients with NAC Stage I ATTR-CM at diagnosis included in the analyses (623 from UK and 256 from France); 109 (12%) were Stage Ia and 770 (88%) were Stage Ib. In the UK cohort, 74 (12%) were Stage Ia and 549 (88%) were Stage Ib. Baseline characteristics of all patients are shown in <em><a href="#ehac259-T1" class="usa-link">Table 1</a></em> along with a comparison between those with Stages Ia and Ib disease. NAC ATTR Stage Ia patients were more commonly ATTRwt, and had better biochemical, functional, and echocardiographic parameters of disease compared with Stage Ib patients. A greater proportion of NAC ATTR Stage Ib patients had Perugini Grade ≥2 radionuclide scans compared with patients with Stage Ia disease (99% vs. 90%); both stages were associated with thickening of the ventricular walls [median IVSd 16 mm [interquartile range (IQR) 14–17] and 17 mm ( IQR 15–18) for NAC ATTR Stages Ia and Ib, respectively]. Prevalence of atrial fibrillation, a permanent pacemaker, and carpal tunnel syndrome appeared to be high across the whole cohort when compared with those reported in age-matched control populations from a variety of published sources.<sup><a href="#ehac259-B25" class="usa-link" aria-describedby="ehac259-B25">25–30</a></sup></p>
<section class="tw xbox font-sm" id="ehac259-T1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Patient and disease-related characteristics at diagnosis in 879 patients with National Amyloidosis Centre Stage I transthyretin amyloid cardiomyopathy</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col valign="top" align="left" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1"></th>
<th align="left" rowspan="1" colspan="1"></th>
<th align="center" rowspan="1" colspan="1">All patients (<em>n</em> = 879)</th>
<th align="center" rowspan="1" colspan="1">Stage Ia (<em>n</em> = 109)</th>
<th align="center" rowspan="1" colspan="1">Stage Ib (<em>n</em> = 770)</th>
<th align="center" rowspan="1" colspan="1">
<em>P</em>-value Ia vs. Ib</th>
</tr></thead>
<tbody>
<tr>
<td colspan="2" rowspan="1">Age at diagnosis (years)</td>
<td rowspan="1" colspan="1">77 (71–82)</td>
<td rowspan="1" colspan="1">75 (71–80)</td>
<td rowspan="1" colspan="1">77 (71–80)</td>
<td rowspan="1" colspan="1">0.032</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Amyloid type</td>
<td rowspan="1" colspan="1">ATTRwt, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">698 (79)</td>
<td rowspan="1" colspan="1">99 (91)</td>
<td rowspan="1" colspan="1">599 (78)</td>
<td rowspan="1" colspan="1">0.002</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">ATTRv, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">181 (21)</td>
<td rowspan="1" colspan="1">10 (9)</td>
<td rowspan="1" colspan="1">171 (22)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Year of diagnosis</td>
<td rowspan="1" colspan="1">2018–20</td>
<td rowspan="1" colspan="1">420 (48)</td>
<td rowspan="1" colspan="1">56 (51)</td>
<td rowspan="1" colspan="1">364 (47)</td>
<td rowspan="1" colspan="1">0.540</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">2015–17</td>
<td rowspan="1" colspan="1">294 (33)</td>
<td rowspan="1" colspan="1">37 (34)</td>
<td rowspan="1" colspan="1">257 (33)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">2012–14</td>
<td rowspan="1" colspan="1">131 (15)</td>
<td rowspan="1" colspan="1">13 (12)</td>
<td rowspan="1" colspan="1">118 (15)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">2009–11</td>
<td rowspan="1" colspan="1">34 (4)</td>
<td rowspan="1" colspan="1">3 (3)</td>
<td rowspan="1" colspan="1">31 (4)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">Male sex, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">775 (88)</td>
<td rowspan="1" colspan="1">101 (93)</td>
<td rowspan="1" colspan="1">674 (88)</td>
<td rowspan="1" colspan="1">0.121</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Caucasian ancestry, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">684 (78)</td>
<td rowspan="1" colspan="1">89 (82)</td>
<td rowspan="1" colspan="1">595 (77)</td>
<td rowspan="1" colspan="1">0.303</td>
</tr>
<tr>
<td colspan="2" rowspan="1">ATTR histology, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">359 (41)</td>
<td rowspan="1" colspan="1">46 (42)</td>
<td rowspan="1" colspan="1">313 (41)</td>
<td rowspan="1" colspan="1">0.758</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Meets non-biopsy criteria, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">752 (86)</td>
<td rowspan="1" colspan="1">83 (76)</td>
<td rowspan="1" colspan="1">669 (87)</td>
<td rowspan="1" colspan="1">0.003</td>
</tr>
<tr>
<td colspan="2" rowspan="1">NT-proBNP (ng/L)</td>
<td rowspan="1" colspan="1">1496 (913–2254)</td>
<td rowspan="1" colspan="1">367 (205–480)</td>
<td rowspan="1" colspan="1">1684 (1130–2342)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Troponin T (ng/L) (<em>n</em> = 861)</td>
<td rowspan="1" colspan="1">45 (31–64)</td>
<td rowspan="1" colspan="1">27 (20–38)</td>
<td rowspan="1" colspan="1">48 (34–66)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">eGFR (mL/min/1.73 m<sup>2</sup>)</td>
<td rowspan="1" colspan="1">70 (59–81)</td>
<td rowspan="1" colspan="1">76 (66–88)</td>
<td rowspan="1" colspan="1">69 (58–81)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Chronic kidney disease stage, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">I</td>
<td rowspan="1" colspan="1">120 (14)</td>
<td rowspan="1" colspan="1">26 (24)</td>
<td rowspan="1" colspan="1">94 (12)</td>
<td rowspan="1" colspan="1">0.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">II</td>
<td rowspan="1" colspan="1">530 (60)</td>
<td rowspan="1" colspan="1">64 (59)</td>
<td rowspan="1" colspan="1">466 (61)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">IIIa</td>
<td rowspan="1" colspan="1">229 (26)</td>
<td rowspan="1" colspan="1">19 (17)</td>
<td rowspan="1" colspan="1">210 (27)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">Alkaline phosphatase (μ/L) (<em>n</em> = 866)</td>
<td rowspan="1" colspan="1">81 (63–103)</td>
<td rowspan="1" colspan="1">72 (58–91)</td>
<td rowspan="1" colspan="1">82 (65–105)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Gamma GT (μ/L) (<em>n</em> = 856)</td>
<td rowspan="1" colspan="1">58 (31–112)</td>
<td rowspan="1" colspan="1">33 (22–62)</td>
<td rowspan="1" colspan="1">63 (34–117)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Serum albumin (g/L) (<em>n</em> = 740)</td>
<td rowspan="1" colspan="1">44 (42–46)</td>
<td rowspan="1" colspan="1">44 (42–47)</td>
<td rowspan="1" colspan="1">44 (42–46)</td>
<td rowspan="1" colspan="1">0.093</td>
</tr>
<tr>
<td colspan="2" rowspan="1">IVSd (mm) (<em>n</em> = 865)</td>
<td rowspan="1" colspan="1">17 (15–18)</td>
<td rowspan="1" colspan="1">16 (14–17)</td>
<td rowspan="1" colspan="1">17 (15–18)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">LVPW (mm) (<em>n</em> = 858)</td>
<td rowspan="1" colspan="1">16 (14–18)</td>
<td rowspan="1" colspan="1">15 (13–16)</td>
<td rowspan="1" colspan="1">16 (14–18)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">LVEF (%) (<em>n</em> = 854)</td>
<td rowspan="1" colspan="1">51 (45–58)</td>
<td rowspan="1" colspan="1">58 (54–61)</td>
<td rowspan="1" colspan="1">51 (44–57)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">DPD/HDMP grade, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1">22 (3)</td>
<td rowspan="1" colspan="1">11 (10)</td>
<td rowspan="1" colspan="1">11 (1)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">≥2</td>
<td rowspan="1" colspan="1">857 (97)</td>
<td rowspan="1" colspan="1">98 (90)</td>
<td rowspan="1" colspan="1">759 (99)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">Systolic blood pressure (mmHg) (<em>n</em> = 871)</td>
<td rowspan="1" colspan="1">128 (118–141)</td>
<td rowspan="1" colspan="1">131 (122–143)</td>
<td rowspan="1" colspan="1">127 (117–140)</td>
<td rowspan="1" colspan="1">0.022</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Diastolic blood pressure (mmHg) (<em>n</em> = 871)</td>
<td rowspan="1" colspan="1">75 (69–82)</td>
<td rowspan="1" colspan="1">76 (70–84)</td>
<td rowspan="1" colspan="1">75 (69–81)</td>
<td rowspan="1" colspan="1">0.222</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Six-min walk test distance (m) (<em>n</em> = 636)</td>
<td rowspan="1" colspan="1">360 (255–444)</td>
<td rowspan="1" colspan="1">430 (345–506)</td>
<td rowspan="1" colspan="1">354 (240–436)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">NYHA class, <em>n</em> (%) (<em>n</em> = 870)</td>
<td rowspan="1" colspan="1">I</td>
<td rowspan="1" colspan="1">126 (15)</td>
<td rowspan="1" colspan="1">40 (38)</td>
<td rowspan="1" colspan="1">86 (11)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">II</td>
<td rowspan="1" colspan="1">611 (70)</td>
<td rowspan="1" colspan="1">58 (55)</td>
<td rowspan="1" colspan="1">553 (72)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">≥III</td>
<td rowspan="1" colspan="1">133 (15)</td>
<td rowspan="1" colspan="1">8 (8)</td>
<td rowspan="1" colspan="1">125 (16)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">Loop diuretic, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">536 (61)</td>
<td rowspan="1" colspan="1">32 (29)</td>
<td rowspan="1" colspan="1">504 (66)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Thiazide diuretic, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">52 (6)</td>
<td rowspan="1" colspan="1">9 (8)</td>
<td rowspan="1" colspan="1">43 (6)</td>
<td rowspan="1" colspan="1">0.270</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Mineralocorticoid receptor antagonist, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">142 (16)</td>
<td rowspan="1" colspan="1">8 (7)</td>
<td rowspan="1" colspan="1">134 (17)</td>
<td rowspan="1" colspan="1">0.008</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Digoxin, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">32 (4)</td>
<td rowspan="1" colspan="1">5 (5)</td>
<td rowspan="1" colspan="1">27 (4)</td>
<td rowspan="1" colspan="1">0.577</td>
</tr>
<tr>
<td colspan="2" rowspan="1">ACE inhibitor, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">311 (35)</td>
<td rowspan="1" colspan="1">30 (28)</td>
<td rowspan="1" colspan="1">281 (37)</td>
<td rowspan="1" colspan="1">0.067</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Angiotensin receptor blocker, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">166 (19)</td>
<td rowspan="1" colspan="1">19 (17)</td>
<td rowspan="1" colspan="1">147 (19)</td>
<td rowspan="1" colspan="1">0.674</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Beta blocker, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">304 (35)</td>
<td rowspan="1" colspan="1">18 (17)</td>
<td rowspan="1" colspan="1">286 (37)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
</tbody>
</table></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col valign="top" align="left" span="1">
<col valign="top" align="left" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1"></th>
<th align="left" rowspan="1" colspan="1"></th>
<th align="center" rowspan="1" colspan="1">All patients</th>
<th align="center" rowspan="1" colspan="1">Controls</th>
<th align="center" rowspan="1" colspan="1">Stage Ia</th>
<th align="center" rowspan="1" colspan="1">Stage Ib</th>
<th align="center" rowspan="1" colspan="1">
<em>P</em>-value</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Carpal tunnel syndrome, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">Unilateral</td>
<td rowspan="1" colspan="1">119 (14)</td>
<td rowspan="1" colspan="1">&lt;8.1%<sup><a href="#ehac259-B30" class="usa-link" aria-describedby="ehac259-B30">30</a></sup>
</td>
<td rowspan="1" colspan="1">16 (15)</td>
<td rowspan="1" colspan="1">103 (13)</td>
<td rowspan="1" colspan="1">0.710</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Bilateral</td>
<td rowspan="1" colspan="1">423 (48)</td>
<td rowspan="1" colspan="1">&lt;8.1%<sup><a href="#ehac259-B30" class="usa-link" aria-describedby="ehac259-B30">30</a></sup>
</td>
<td rowspan="1" colspan="1">66 (61)</td>
<td rowspan="1" colspan="1">357 (46)</td>
<td rowspan="1" colspan="1">0.006</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Spinal stenosis, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">114 (13)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">20 (18)</td>
<td rowspan="1" colspan="1">94 (12)</td>
<td rowspan="1" colspan="1">0.074</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Joint replacement, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">174 (20)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">25 (23)</td>
<td rowspan="1" colspan="1">149 (19)</td>
<td rowspan="1" colspan="1">0.379</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Atrial fibrillation, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">271 (31)</td>
<td rowspan="1" colspan="1">8%<sup><a href="#ehac259-B25" class="usa-link" aria-describedby="ehac259-B25">25</a></sup>
</td>
<td rowspan="1" colspan="1">33 (31)</td>
<td rowspan="1" colspan="1">238 (32)</td>
<td rowspan="1" colspan="1">0.846</td>
</tr>
<tr>
<td colspan="2" rowspan="1">PPM, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">132 (15)</td>
<td rowspan="1" colspan="1">3%<sup><a href="#ehac259-B26" class="usa-link" aria-describedby="ehac259-B26">26</a></sup>
</td>
<td rowspan="1" colspan="1">14 (13)</td>
<td rowspan="1" colspan="1">118 (15)</td>
<td rowspan="1" colspan="1">0.497</td>
</tr>
<tr>
<td colspan="2" rowspan="1">ICD, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">47 (5)</td>
<td rowspan="1" colspan="1">—</td>
<td rowspan="1" colspan="1">1 (1)</td>
<td rowspan="1" colspan="1">46 (6)</td>
<td rowspan="1" colspan="1">0.028</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Hypertension, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">388 (44)</td>
<td rowspan="1" colspan="1">64%<sup><a href="#ehac259-B27" class="usa-link" aria-describedby="ehac259-B27">27</a></sup>
</td>
<td rowspan="1" colspan="1">47 (43)</td>
<td rowspan="1" colspan="1">341 (44)</td>
<td rowspan="1" colspan="1">0.810</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Ischaemic heart disease, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">136 (16)</td>
<td rowspan="1" colspan="1">16%<sup><a href="#ehac259-B28" class="usa-link" aria-describedby="ehac259-B28">28</a></sup>
</td>
<td rowspan="1" colspan="1">10 (9)</td>
<td rowspan="1" colspan="1">126 (16)</td>
<td rowspan="1" colspan="1">0.052</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Stroke or TIA, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">96 (11)</td>
<td rowspan="1" colspan="1">9%<sup><a href="#ehac259-B28" class="usa-link" aria-describedby="ehac259-B28">28</a></sup>
</td>
<td rowspan="1" colspan="1">9 (8)</td>
<td rowspan="1" colspan="1">87 (11)</td>
<td rowspan="1" colspan="1">0.341</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Diabetes mellitus, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">143 (16)</td>
<td rowspan="1" colspan="1">14%<sup><a href="#ehac259-B29" class="usa-link" aria-describedby="ehac259-B29">29</a></sup>
</td>
<td rowspan="1" colspan="1">22 (20)</td>
<td rowspan="1" colspan="1">121 (16)</td>
<td rowspan="1" colspan="1">0.237</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/ehac259-T1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="ehac259-tblfn1"><p>Values are displayed as median (interquartile range) unless otherwise stated. <em>P</em>-values represent comparison testing between NAC ATTR Stages Ia and Ib by Kruskal–Wallis test for numerical variables and χ<sup>2</sup> test for categorical variables. NT-proBNP, N-terminal pro-B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; IVSd, interventricular septal wall thickness at end-diastole; LVPW, left ventricular posterior wall thickness; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PPM, permanent pacemaker; ICD, implantable cardioverter defibrillator; TIA, transient ischaemic attack. Controls report the disease prevalence in matched general population groups from a variety of published sources. Number reported where missing data are present within a given variable. NAC ATTR Stage Ia is defined as: NT-proBNP ≤ 500 ng/L or ≤1000 ng/L in the presence of atrial fibrillation with a loop diuretic equivalent requirement of &lt;0.75 mg/kg, and NAC ATTR Stage Ib is defined as: NT-proBNP &gt; 500 ng/L or &gt;1000 ng/L in the presence of atrial fibrillation or a loop diuretic equivalent requirement of ≥0.75 mg/kg.</p></div></div></section><p>Patient characteristics stratified by grade of cardiac uptake on radionuclide scintigraphy are shown in <em><a href="#ehac259-T2" class="usa-link">Table 2</a></em>. Patients with Perugini Grade ≥2 cardiac uptake had worse clinical, biochemical, functional, and echocardiographic parameters of cardiac disease when compared with those with Perugini Grade 1 cardiac uptake.</p>
<section class="tw xbox font-sm" id="ehac259-T2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Baseline characteristics of patients with National Amyloidosis Centre Stage I transthyretin amyloid cardiomyopathy stratified by grade of cardiac uptake by radionuclide scanning</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col valign="top" align="left" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2" colspan="1"></th>
<th align="left" rowspan="2" colspan="1"></th>
<th align="center" rowspan="1" colspan="1">Grade 1</th>
<th align="center" rowspan="1" colspan="1">Grade ≥2</th>
<th align="center" rowspan="2" colspan="1">
<em>P</em>-value</th>
</tr>
<tr>
<th align="center" rowspan="1" colspan="1">(<em>n</em> = 22)</th>
<th align="center" rowspan="1" colspan="1">(<em>n</em> = 857)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="2" rowspan="1">Age at diagnosis (years)</td>
<td rowspan="1" colspan="1">79 (72–83)</td>
<td rowspan="1" colspan="1">77 (71–82)</td>
<td rowspan="1" colspan="1">0.402</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Amyloid type</td>
<td rowspan="1" colspan="1">ATTRwt, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">19 (86)</td>
<td rowspan="1" colspan="1">679 (79)</td>
<td rowspan="1" colspan="1">0.414</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">V122I-ATTRv, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">3 (14)</td>
<td rowspan="1" colspan="1">178 (21)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">Male sex, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">19 (86)</td>
<td rowspan="1" colspan="1">756 (88)</td>
<td rowspan="1" colspan="1">0.791</td>
</tr>
<tr>
<td rowspan="1" colspan="1">NAC ATTR Stage</td>
<td rowspan="1" colspan="1">Ia</td>
<td rowspan="1" colspan="1">11 (50)</td>
<td rowspan="1" colspan="1">98 (11)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Ib</td>
<td rowspan="1" colspan="1">11 (50)</td>
<td rowspan="1" colspan="1">759 (89)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">NT-proBNP (ng/L)</td>
<td rowspan="1" colspan="1">513 (245–1239)</td>
<td rowspan="1" colspan="1">1522 (939–2267)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Troponin T (ng/L)</td>
<td rowspan="1" colspan="1">20 (14–35)</td>
<td rowspan="1" colspan="1">46 (32–64)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">eGFR (mL/min/1.73 m<sup>2</sup>)</td>
<td rowspan="1" colspan="1">73 (61–88)</td>
<td rowspan="1" colspan="1">70 (59–81)</td>
<td rowspan="1" colspan="1">0.381</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Alkaline phosphatase (μ/L)</td>
<td rowspan="1" colspan="1">76 (55–105)</td>
<td rowspan="1" colspan="1">81 (63–103)</td>
<td rowspan="1" colspan="1">0.544</td>
</tr>
<tr>
<td colspan="2" rowspan="1">IVSd (mm)</td>
<td rowspan="1" colspan="1">12 (11–12)</td>
<td rowspan="1" colspan="1">17 (15–18)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">LVPW (mm)</td>
<td rowspan="1" colspan="1">12 (11–13)</td>
<td rowspan="1" colspan="1">16 (14–18)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">LVEF (%)</td>
<td rowspan="1" colspan="1">55 (45–60)</td>
<td rowspan="1" colspan="1">51 (45–58)</td>
<td rowspan="1" colspan="1">0.340</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Systolic blood pressure (mmHg)</td>
<td rowspan="1" colspan="1">132 (121–148)</td>
<td rowspan="1" colspan="1">128 (117–141)</td>
<td rowspan="1" colspan="1">0.216</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Six-min walk test distance (m)</td>
<td rowspan="1" colspan="1">365 (235–460)</td>
<td rowspan="1" colspan="1">360 (256–443)</td>
<td rowspan="1" colspan="1">0.696</td>
</tr>
<tr>
<td rowspan="1" colspan="1">NYHA class, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">I</td>
<td rowspan="1" colspan="1">9 (41)</td>
<td rowspan="1" colspan="1">117 (14)</td>
<td rowspan="1" colspan="1">0.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">II</td>
<td rowspan="1" colspan="1">12 (54)</td>
<td rowspan="1" colspan="1">599 (71)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">≥III</td>
<td rowspan="1" colspan="1">1 (5)</td>
<td rowspan="1" colspan="1">132 (16)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Carpal tunnel syndrome, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">Unilateral</td>
<td rowspan="1" colspan="1">3 (14)</td>
<td rowspan="1" colspan="1">116 (14)</td>
<td rowspan="1" colspan="1">0.989</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Bilateral</td>
<td rowspan="1" colspan="1">12 (55)</td>
<td rowspan="1" colspan="1">411 (48)</td>
<td rowspan="1" colspan="1">0.541</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Spinal stenosis, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">3 (14)</td>
<td rowspan="1" colspan="1">111 (13)</td>
<td rowspan="1" colspan="1">0.925</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Joint replacement, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">2 (9)</td>
<td rowspan="1" colspan="1">172 (20)</td>
<td rowspan="1" colspan="1">0.202</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Loop diuretic, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">8 (36)</td>
<td rowspan="1" colspan="1">528 (62)</td>
<td rowspan="1" colspan="1">0.017</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Thiazide diuretic, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">1 (5)</td>
<td rowspan="1" colspan="1">51 (6)</td>
<td rowspan="1" colspan="1">0.782</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Mineralocorticoid receptor antagonist, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">1 (5)</td>
<td rowspan="1" colspan="1">141 (17)</td>
<td rowspan="1" colspan="1">0.134</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Digoxin, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">1 (5)</td>
<td rowspan="1" colspan="1">31 (4)</td>
<td rowspan="1" colspan="1">0.820</td>
</tr>
<tr>
<td colspan="2" rowspan="1">ACE inhibitor, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">3 (14)</td>
<td rowspan="1" colspan="1">308 (36)</td>
<td rowspan="1" colspan="1">0.031</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Angiotensin receptor blocker, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">2 (9)</td>
<td rowspan="1" colspan="1">164 (19)</td>
<td rowspan="1" colspan="1">0.234</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Beta blocker, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">4 (18)</td>
<td rowspan="1" colspan="1">300 (35)</td>
<td rowspan="1" colspan="1">0.101</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Atrial fibrillation, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">7 (32)</td>
<td rowspan="1" colspan="1">264 (31)</td>
<td rowspan="1" colspan="1">0.963</td>
</tr>
<tr>
<td colspan="2" rowspan="1">PPM, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">2 (9)</td>
<td rowspan="1" colspan="1">130 (15)</td>
<td rowspan="1" colspan="1">0.431</td>
</tr>
<tr>
<td colspan="2" rowspan="1">ICD, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">1 (5)</td>
<td rowspan="1" colspan="1">46 (5)</td>
<td rowspan="1" colspan="1">0.866</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Hypertension, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">7 (32)</td>
<td rowspan="1" colspan="1">381 (45)</td>
<td rowspan="1" colspan="1">0.237</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Ischaemic heart disease, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">3 (14)</td>
<td rowspan="1" colspan="1">133 (16)</td>
<td rowspan="1" colspan="1">0.809</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Stroke or TIA, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">3 (14)</td>
<td rowspan="1" colspan="1">93 (11)</td>
<td rowspan="1" colspan="1">0.679</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Diabetes mellitus, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">5 (23)</td>
<td rowspan="1" colspan="1">138 (16)</td>
<td rowspan="1" colspan="1">0.406</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/ehac259-T2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="ehac259-tblfn2"><p>Values displayed as median (interquartile range) unless otherwise stated. Heart:mediastinal ratio of &gt;1.21 by <sup>99m</sup>Tc-HMDP scintigraphy considered equivalent to Perugini Grade ≥2 cardiac uptake <sup>99m</sup>Tc-DPD. <em>P-</em>values represent comparison testing between patients with a Perugini Grade 1 cardiac uptake vs. those with Perugini Grade ≥2 cardiac uptake at diagnosis by the Kruskal–Wallis test for numerical variables and χ<sup>2</sup> test for categorical variables.</p></div></div></section></section><section id="ehac259-s3.2"><h3 class="pmc_sec_title">Patient survival</h3>
<p>At a median follow-up of 21 (IQR 8–40) months, 120 (14%) patients had died, and the overall median estimated survival was 87 (95% CI 63—not met) months.</p>
<p>Univariable Cox regression analyses investigating the association between mortality and a range of patient and disease-related variables for the whole cohort are shown in <a href="#sup1" class="usa-link">Supplementary material online</a>, <em><a href="#sup1" class="usa-link">Table 1</a></em>. There was a significant association between mortality and <em>TTR</em> genotype, NT-proBNP, troponin T, serum albumin, IVSd, NYHA class, diabetes mellitus, loop diuretic dose, mineralocorticoid requirement, LVEF, and systolic blood pressure. Multivariable analyses identified higher NT-proBNP (<a href="#sup1" class="usa-link">Supplementary material online</a>, <em><a href="#sup1" class="usa-link">Table 2</a></em>; Harrell’s <em>c</em>-statistic 0.89) or NAC ATTR Stage Ib (<em><a href="#ehac259-T3" class="usa-link">Table 3</a></em>: categorical variable vs. Stage Ia; Harrell’s <em>c</em>-statistic = 0.75), ATTRv, and higher troponin T at diagnosis as independent predictors of mortality. N-terminal pro-B-type natriuretic peptide at diagnosis was the most powerful independent predictor of mortality [HR 4.36 (95% CI 1.69–11.30); <em>P</em> = 0.002, <a href="#sup1" class="usa-link">Supplementary material online</a>, <em><a href="#sup1" class="usa-link">Table 2</a></em>].</p>
<section class="tw xbox font-sm" id="ehac259-T3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Multivariable Cox regression analyses of mortality indicators at diagnosis in NAC Stage I ATTR-CM</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col valign="top" align="left" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1"></th>
<th align="left" rowspan="1" colspan="1"></th>
<th align="center" colspan="3" rowspan="1">Multivariable</th>
</tr>
<tr>
<th rowspan="1" colspan="1"></th>
<th rowspan="1" colspan="1"></th>
<th align="left" rowspan="1" colspan="1">HR</th>
<th align="center" rowspan="1" colspan="1">95% CI</th>
<th align="center" rowspan="1" colspan="1">
<em>P</em>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">NAC ATTR Stage</td>
<td rowspan="1" colspan="1">Ia</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1">1.23–20.87</td>
<td rowspan="1" colspan="1">0.025</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Ib</td>
<td rowspan="1" colspan="1">5.06</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">Age (per 10 years)</td>
<td rowspan="1" colspan="1">1.14</td>
<td rowspan="1" colspan="1">0.85–1.52</td>
<td rowspan="1" colspan="1">0.374</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Male sex</td>
<td rowspan="1" colspan="1">1.28</td>
<td rowspan="1" colspan="1">0.70–2.37</td>
<td rowspan="1" colspan="1">0.424</td>
</tr>
<tr>
<td colspan="2" rowspan="1">V122I-ATTRv amyloid type</td>
<td rowspan="1" colspan="1">2.33</td>
<td rowspan="1" colspan="1">1.54–3.53</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Troponin T (per 100 ng/L)</td>
<td rowspan="1" colspan="1">2.76</td>
<td rowspan="1" colspan="1">1.92–3.97</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1">NYHA class</td>
<td rowspan="1" colspan="1">I</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">II</td>
<td rowspan="1" colspan="1">1.96</td>
<td rowspan="1" colspan="1">0.90–4.29</td>
<td rowspan="1" colspan="1">0.091</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">III</td>
<td rowspan="1" colspan="1">1.78</td>
<td rowspan="1" colspan="1">0.75–4.27</td>
<td rowspan="1" colspan="1">0.194</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/ehac259-T3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="ehac259-tblfn3"><p>NAC ATTR Stage Ia is defined as: NT-proBNP ≤ 500 or ≤1000 ng/L in the presence of atrial fibrillation with a loop diuretic equivalent requirement of &lt;0.75 mg/kg, and NAC ATTR Stage Ib is defined as: NT-proBNP &gt; 500 or &gt;1000 ng/L in the presence of atrial fibrillation or a loop diuretic equivalent requirement of ≥0.75 mg/kg. NYHA, New York Heart Association; Harrell’s <em>c</em>-statistic 0.75.</p></div></div></section><p>Median estimated survival by KM analysis among patients with NAC ATTR Stage Ia disease was not met at 100 months, and was 75 months (95% CI: 57–93) among those with Stage Ib disease (<em>P</em> &lt; 0.001, <em><a href="#ehac259-ehac259ga1" class="usa-link">Structured Graphical Abstract</a></em>, <em><a href="#ehac259-F1" class="usa-link">Figure 1A</a></em>). When limited to the UK cohort, the median estimated survival of patients with NAC ATTR Stage Ia disease was not met at 100 months, and there was no evidence of a difference in survival between UK NAC Stage Ia patients and matched UK general population controls (<em>P</em> = 0.297; <em><a href="#ehac259-F1" class="usa-link">Figure 1B</a></em>). The median estimated survival of UK patients with NAC ATTR Stage Ib disease was 85 (95% CI: undefined) months which was significantly reduced when compared with matched UK general population controls (<em>P</em> &lt; 0.0001; <em><a href="#ehac259-F1" class="usa-link">Figure 1C</a></em>).</p>
<figure class="fig xbox font-sm" id="ehac259-F1"><h4 class="obj_head">Figure 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9279112_ehac259f1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0544/9279112/a5475bf316b4/ehac259f1.jpg" loading="lazy" height="1791" width="798" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/ehac259-F1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>(<em>A</em>) Kaplan–Meier survival curves stratified by National Amyloidosis Centre transthyretin amyloid stage for the whole cohort. Median estimated survival among patients with Stage Ia was not met at 100 months and was 75 months (95% CI: 57–93) in patients with Stage Ib (<em>P</em> = 0.0002). (<em>B</em>) Survival of the UK National Amyloidosis Centre cohort with Stage Ia compared with matched UK general population controls. Median estimated survival was not met in either group at 100 months; there was no evidence of a difference in survival between the two groups (<em>P</em> = 0.297). (<em>C</em>) Survival of the UK National Amyloidosis Centre cohort with Stage Ib compared with matched UK general population controls. Median estimated survival among patients with Stage Ib was 85 months (95% CI: undefined), and was not met at 100 months in a matched UK general population control group; patient survival was reduced in the Stage Ib group compared with UK general population controls (<em>P</em> &lt; 0.0001).</p></figcaption></figure></section><section id="ehac259-s3.3"><h3 class="pmc_sec_title">Cardiovascular and non-cardiovascular morbidity in Stage Ia ATTR amyloidosis</h3>
<p>Among the 109 patients from the whole cohort who were NAC ATTR Stage Ia at diagnosis, followed for a median of 28 months (range: 8–46), regular diuretic use increased from 39% of patients at diagnosis to 56% of patients, prevalence of atrial fibrillation increased from 31% at diagnosis to 40% of patients, NYHA Class ≥II heart failure increased from 62% to 82% of patients, cardiovascular accident or transient ischaemic attack from 8% to 15% of patients, and permanent pacemaker implants from 13% to 20% of patients. Of the six permanent pacemakers implanted after diagnosis of ATTR-CM, three were for complete heart block and the remainder for non-specified bradyarrhythmias. The median NT-proBNP increase during follow-up was 145 ng/L/year (IQR: 47–440) and median eGFR reduction was 2.8 mL/min/1.73 m<sup>2</sup>/year (IQR: 0–7). Twenty-one of 80 (26%) patients with follow-up biomarkers went from Stage Ia to Stage Ib ATTR-CM and 14 (18%) developed NAC ATTR Stage ≥ II disease during the follow-up period.</p>
<p>Among 63 patients with NAC ATTR Stage Ia disease who had a primary cardiovascular presentation, cardiac biomarkers, cardiac imaging, and functional markers of cardiac disease were significantly worse than in the 46 patients with a primary non-cardiovascular presentation (<em><a href="#ehac259-T4" class="usa-link">Table 4</a></em>). Similarly, a significantly higher proportion of patients with a primary cardiovascular presentation required diuretic therapy, had atrial fibrillation and met the non-biopsy diagnostic criteria for ATTR-CM. The commonest cardiovascular presentations were cardiac failure (60%) and atrial arrhythmias (25%) (<em><a href="#ehac259-T4" class="usa-link">Table 4</a></em>).</p>
<section class="tw xbox font-sm" id="ehac259-T4"><h4 class="obj_head">Table 4.</h4>
<div class="caption p"><p>Baseline characteristics of 109 patients diagnosed with NAC ATTR Stage Ia disease stratified by clinical presentation</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col valign="top" align="left" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
<col valign="top" align="center" span="1">
</colgroup>
<thead>
<tr>
<th align="left" rowspan="3" colspan="1"></th>
<th align="center" rowspan="3" colspan="1"></th>
<th align="center" colspan="2" rowspan="1">Cardiovascular presentation</th>
<th align="center" rowspan="3" colspan="1">
<em>P</em>-value</th>
</tr>
<tr>
<th align="center" rowspan="1" colspan="1">No</th>
<th align="center" rowspan="1" colspan="1">Yes</th>
</tr>
<tr>
<th align="center" rowspan="1" colspan="1">(<em>n</em> = 46)</th>
<th align="center" rowspan="1" colspan="1">(<em>n</em> = 63)</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Age (years)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">75 (70–80)</td>
<td rowspan="1" colspan="1">75 (71–80)</td>
<td rowspan="1" colspan="1">0.988</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Male sex, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">41 (89)</td>
<td rowspan="1" colspan="1">60 (95)</td>
<td rowspan="1" colspan="1">0.227</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Caucasian ancestry, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">35 (76)</td>
<td rowspan="1" colspan="1">54 (86)</td>
<td rowspan="1" colspan="1">0.200</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Amyloid type</td>
<td rowspan="1" colspan="1">ATTRwt, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">39 (85)</td>
<td rowspan="1" colspan="1">60 (95)</td>
<td rowspan="1" colspan="1">0.062</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">V122I-ATTRv, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">7 (15)</td>
<td rowspan="1" colspan="1">3 (5)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">ATTR histology, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">24 (52)</td>
<td rowspan="1" colspan="1">22 (35)</td>
<td rowspan="1" colspan="1">0.072</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Meets non-biopsy criteria, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">30 (65)</td>
<td rowspan="1" colspan="1">53 (84)</td>
<td rowspan="1" colspan="1">0.022</td>
</tr>
<tr>
<td colspan="2" rowspan="1">NT-proBNP (ng/L)</td>
<td rowspan="1" colspan="1">263 (155–456)</td>
<td rowspan="1" colspan="1">403 (288–668)</td>
<td rowspan="1" colspan="1">0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Troponin T (ng/L)</td>
<td rowspan="1" colspan="1">21 (17–30)</td>
<td rowspan="1" colspan="1">32 (24–48)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">eGFR (mL/min/1.73 m<sup>2</sup>)</td>
<td rowspan="1" colspan="1">76 (71–90)</td>
<td rowspan="1" colspan="1">74 (64–88)</td>
<td rowspan="1" colspan="1">0.237</td>
</tr>
<tr>
<td colspan="2" rowspan="1">IVSd (mm)</td>
<td rowspan="1" colspan="1">15 (12–17)</td>
<td rowspan="1" colspan="1">16 (15–17)</td>
<td rowspan="1" colspan="1">0.024</td>
</tr>
<tr>
<td rowspan="1" colspan="1">DPD/HDMP grade, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">1</td>
<td rowspan="1" colspan="1">11 (24)</td>
<td rowspan="1" colspan="1">0 (0)</td>
<td rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">≥2</td>
<td rowspan="1" colspan="1">35 (76)</td>
<td rowspan="1" colspan="1">63 (100)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">NYHA class, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">I</td>
<td rowspan="1" colspan="1">25 (57)</td>
<td rowspan="1" colspan="1">15 (24)</td>
<td rowspan="1" colspan="1">0.003</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">II</td>
<td rowspan="1" colspan="1">16 (36)</td>
<td rowspan="1" colspan="1">42 (68)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">≥III</td>
<td rowspan="1" colspan="1">3 (7)</td>
<td rowspan="1" colspan="1">5 (8)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">Atrial fibrillation, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">6 (13)</td>
<td rowspan="1" colspan="1">27 (43)</td>
<td rowspan="1" colspan="1">0.001</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Hypertension, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">19 (41)</td>
<td rowspan="1" colspan="1">28 (44)</td>
<td rowspan="1" colspan="1">0.744</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Diabetes mellitus, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">9 (20)</td>
<td rowspan="1" colspan="1">13 (21)</td>
<td rowspan="1" colspan="1">0.891</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Pacemaker, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">6 (13)</td>
<td rowspan="1" colspan="1">8 (13)</td>
<td rowspan="1" colspan="1">0.958</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Stroke or TIA, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">3 (7)</td>
<td rowspan="1" colspan="1">6 (10)</td>
<td rowspan="1" colspan="1">0.574</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Diuretic requirement, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">10 (22)</td>
<td rowspan="1" colspan="1">33 (52)</td>
<td rowspan="1" colspan="1">0.001</td>
</tr>
<tr><td colspan="5" rowspan="1">
<em>
<strong>Presentation</strong>
</em>
</td></tr>
<tr>
<td colspan="2" rowspan="1">Cardiac failure, <em>n</em> (%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">38 (60)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="3" rowspan="1">Atrial fibrillation/flutter, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">16 (25)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">Complete heart block, <em>n</em> (%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">1 (2)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">Stroke, <em>n</em> (%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">3 (5)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">Chest pain, <em>n</em> (%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">3 (5)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">Aortic stenosis, <em>n</em> (%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">1 (2)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">Syncope</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">1 (2)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">Asymptomatic ECG abnormality, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">5 (11)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td colspan="2" rowspan="1">Asymptomatic cardiac imaging abnormality, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">22 (48)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Histology</td>
<td rowspan="1" colspan="1">Carpal tunnel, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">5 (11)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Gastrointestinal, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">6 (13)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Bladder, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">7 (15)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Prostate, <em>n</em> (%)</td>
<td rowspan="1" colspan="1">1 (2)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/ehac259-T4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="ehac259-tblfn4"><p>Values displayed as median (interquartile range) unless stated otherwise. <em>P</em>-values represent comparison testing between NAC ATTR Stage Ia patients with a symptomatic cardiovascular clinical presentation vs. those with a non-cardiovascular clinical presentation at diagnosis by the Kruskal–Wallis test for numerical variables and χ<sup>2</sup> test for categorical variables. NAC ATTR Stage Ia is defined as: NT-proBNP ≤ 500 or ≤1000 ng/L in the presence of atrial fibrillation with a loop diuretic equivalent requirement of &lt;0.75 mg/kg.</p></div></div></section><p>Non-cardiovascular clinical presentations included urological symptoms accompanied by histological evidence of bladder or prostatic ATTR amyloid, carpal tunnel syndrome with ATTR amyloid deposits in the flexor retinaculum or tenosynovium, and incidental discovery of ATTR amyloid deposits in the gastrointestinal tract. Biopsy sites in which ATTR amyloid deposits were identified in patients with a non-cardiovascular primary clinical presentation are shown in <em><a href="#ehac259-T4" class="usa-link">Table 4</a></em>. Perugini Grade ≥2 cardiac uptake was identified by imaging (usually in the context of screening for it) in 76% of patients with a primary non-cardiovascular presentation (<em><a href="#ehac259-T4" class="usa-link">Table 4</a></em>). Follow-up data were available for 43 of 46 Stage Ia patients with a non-cardiovascular primary clinical presentation and after a median follow-up of 19 months (IQR: 8–50), 12 (28%) patients had atrial fibrillation, 8 (19%) had a permanent pacemaker, 6 (14%) had a history of stroke or transient ischaemic attack, 29 (69%) had NYHA Class ≥II heart failure symptoms, and 16 (37%) required diuretic therapy; median NT-proBNP increase was 109 ng/L/year (IQR: 23–276) and 9 of 32 (28%) patients with follow-up biomarkers had progressed to NAC ATTR Stage ≥ Ib. The median estimated survival of patients with NAC ATTR Stage Ia was not met at 80 months in both patients with and without a cardiovascular presentation (<em>P</em> = 0.837).</p></section></section><section id="ehac259-s4"><h2 class="pmc_sec_title">Discussion</h2>
<p>Increased awareness of ATTR-CM among cardiologists and improved diagnostic techniques are leading to a reduction in diagnostic delays with a consequent increase in the proportion of patients diagnosed with early-stage disease, defined as NAC ATTR Stage I, a trend which is likely to continue.<sup><a href="#ehac259-B6" class="usa-link" aria-describedby="ehac259-B6">6–9</a>,<a href="#ehac259-B13" class="usa-link" aria-describedby="ehac259-B13">13</a></sup> This trend has recently been highlighted by the reported findings from Part 1 of the ATTRibute-CM (acoramidis) study in which the 6  min walk test distance among patients within the placebo arm declined by &lt;10 m in the first year compared with &gt;50 m over the same time period among patients on placebo within the older ATTR-ACT trial (tafamidis).<sup><a href="#ehac259-B10" class="usa-link" aria-describedby="ehac259-B10">10</a>,<a href="#ehac259-B31" class="usa-link" aria-describedby="ehac259-B31">31</a></sup> Here we outline for the first time, the clinical features and natural history of early-stage ATTR-CM in a large cohort of patients with predominant cardiomyopathic <em>TTR</em> genotypes followed in two large European Amyloidosis Centres.</p>
<p>It is noteworthy, although perhaps unsurprising, that the most important independent predictor of mortality in this cohort was NT-proBNP concentration at diagnosis. A diagnostic NT-proBNP concentration of ≤500 ng/L (or ≤1000 ng/L in the context of atrial fibrillation) coupled with a loop diuretic equivalent dose requirement of &lt;0.75 mg/kg, defined here as NAC ATTR Stage Ia, was present in only 109 (12%) of patients. Despite Perugini Grade ≥2 radionuclide scintigraphy in 90% of such patients, only 58% of Stage Ia patients had a primary cardiovascular clinical presentation. A comparison between patients diagnosed with Stages Ia and Ib disease showed a significantly higher proportion of ATTRwt, lower troponin T, higher eGFR, lower ALP, less thickening of left ventricular walls and better LVEF on echocardiography, and a better functional status according to both NYHA class and 6 min walk test in the former group. Median survival was in excess of 100 months from diagnosis in Stage Ia patients, and there was no evidence of a difference in survival between UK NAC Stage Ia patients and matched UK general population controls.</p>
<p>The most common non-cardiac sites in which ATTR amyloid deposits were identified were flexor retinaculum, gastrointestinal tract, and bladder; flexor retinaculum biopsies were obtained at carpal tunnel surgery and bladder biopsies were usually performed for haematuria, whereas the finding of ATTR amyloid in gastrointestinal tract was often ‘incidental’ in association with a second pathology in the relevant organ (e.g. gastric ulcer).</p>
<p>Cardiovascular morbidity at the time of diagnosis was substantial, even in patients with NAC ATTR Stage Ia disease; NYHA Class ≥II heart failure symptoms, regular diuretic use, atrial fibrillation, permanent pacemaker implants, and CVA/TIAs were present in 62%, 39%, 31%, 13%, and 8% such patients, respectively. Furthermore, despite a relatively short median duration of follow-up in this patient subgroup, the proportion of patients with these cardiovascular morbidities increased following diagnosis including among patients who did not have a primary cardiovascular clinical presentation. These findings lend strong support to the argument for considering disease-modifying therapy with TTR stabilisers or <em>TTR</em> gene silencers at the time of identification of ATTR amyloid in patients with cardiac uptake by radionuclide imaging, even in patients without a primary cardiovascular presentation or overt heart failure symptoms.<sup><a href="#ehac259-B10" class="usa-link" aria-describedby="ehac259-B10">10–12</a></sup> It remains to be determined, however, whether therapeutic intervention at this early disease stage will lead to a reduction in cardiovascular morbidity.</p>
<p>Study limitations include the relatively smaller size of the ATTRv-CM population compared with ATTRwt-CM population although this probably reflects true disease prevalence in the respective countries. Other limitations include the relatively short median duration of follow-up, the absence of hospitalization data, the use of internal validation rather than external validation, the absence of data on cause of death, the use of expected survival rather than actual survival for general population analyses, the restriction of general population analyses to the UK cohort, and the potential bias introduced by the fact that patients were followed in large specialist amyloidosis centres rather than across general cardiology as well as other specialty clinics.</p>
<p>In conclusion, the short- and mid-term prognosis of patients diagnosed with Stage Ia ATTR-CM, defined here as an eGFR ≥ 45 mL/min, NT-proBNP ≤ 500 ng/L (or ≤1000 ng/L in the context of atrial fibrillation), and a loop diuretic equivalent dose requirement of &lt;0.75 mg/kg, appears to be good and overall prognosis in the absence of disease-modifying therapy may be comparable to the age and gender-matched general population. However, cardiovascular morbidity is high in patients diagnosed with Stage Ia ATTR-CM and increases further during patient follow-up. Whether early therapeutic intervention with specific anti-amyloid therapies in patients diagnosed with Stage Ia ATTR-CM will reduce cardiovascular morbidity and prolong survival remains to be determined.</p></section><section id="sec18"><h2 class="pmc_sec_title">Supplementary Material</h2>
<section class="sm xbox font-sm" id="sup1"><div class="caption p"><span>ehac259_Supplementary_Data</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/9279112/bin/ehac259_supplementary_data.docx" data-ga-action="click_feat_suppl" class="usa-link">Click here for additional data file.</a><sup> (17.7KB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We thank our many physician colleagues for referring the patients. S.L., A.P., T.D., M.F., and J.D.G. were responsible for conceiving the study, interpreting the results, and drafting the manuscript. M.B., L.C., O.C.C., S.R., O.O., M.K., S.G., S.G., J.A.G., D.R., A.W., A.M.-N., H.J.L., C.J.W., D.F.H., and P.N.H. were responsible for data collection and interpretation.</p>
<p>
<strong>Conflicts of interest</strong>: No COI to report. J.D.G. reports consultancy fees from Alnylam, Ionis, Eidos, and Intellia. D.F.H. reports speaker fees for Alnylam and Akcea Therapeutics UK Ltd. C.J.W. reports honoraria from Akcea, Alnylam, Novartis, and Pfizer. T.D. reports grants, consulting fees, and honoraria from Alnylam, Akcea, Ionis, Prothena, Pfizer, GSK, and Neurimmune.</p></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Steven Law, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Melanie Bezard, 
Referral Center for Cardiac Amyloidosis, Department of Cardiology, Mondor Amyloidosis Network, GRC Amyloid Research Institute, Clinical Investigation Center 006, DHU A-TVB INSERM U955 all at CHU Henri Mondor, UPEC, Créteil, France.</p>
<p>Aviva Petrie, 
Biostatistics Unit, UCL Eastman Dental Institute, University College London, London, UK.</p>
<p>Liza Chacko, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Oliver C Cohen, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Sriram Ravichandran, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Olabisi Ogunbiyi, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Mounira Kharoubi, 
Biostatistics Unit, UCL Eastman Dental Institute, University College London, London, UK.</p>
<p>Sashiananthan Ganeshananthan, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Sharmananthan Ganeshananthan, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Janet A Gilbertson, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Dorota Rowczenio, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Ashutosh Wechalekar, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Ana Martinez-Naharro, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Helen J Lachmann, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Carol J Whelan, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>David F Hutt, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Philip N Hawkins, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Thibaud Damy, 
Referral Center for Cardiac Amyloidosis, Department of Cardiology, Mondor Amyloidosis Network, GRC Amyloid Research Institute, Clinical Investigation Center 006, DHU A-TVB INSERM U955 all at CHU Henri Mondor, UPEC, Créteil, France.</p>
<p>Marianna Fontana, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p>
<p>Julian D Gillmore, 
National Amyloidosis Centre, Division of Medicine, University College London, London, UK.</p></section><section id="ehac259-s5"><h2 class="pmc_sec_title">Supplementary material</h2>
<p>
<a href="#sup1" class="usa-link">Supplementary material</a> is available at <em>European Heart Journal</em> online.</p></section><section id="ref1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="ehac259-B1">
<span class="label">1.</span><cite>
Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in amyloidosis 1987–2019. N Engl J Med 2020;382:1567–1568.</cite> [<a href="https://doi.org/10.1056/NEJMc1917321" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32294353/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Epidemiologic%20and%20survival%20trends%20in%20amyloidosis%201987%E2%80%932019&amp;volume=382&amp;publication_year=2020&amp;pages=1567-1568&amp;pmid=32294353&amp;doi=10.1056/NEJMc1917321&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B2">
<span class="label">2.</span><cite>
Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. 
Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008;40:232–239.</cite> [<a href="https://doi.org/10.1080/07853890701842988" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18382889/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Med&amp;title=Senile%20systemic%20amyloidosis%20affects%2025%%20of%20the%20very%20aged%20and%20associates%20with%20genetic%20variation%20in%20alpha2-macroglobulin%20and%20tau:%20a%20population-based%20autopsy%20study&amp;volume=40&amp;publication_year=2008&amp;pages=232-239&amp;pmid=18382889&amp;doi=10.1080/07853890701842988&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B3">
<span class="label">3.</span><cite>
Mirzoyev SA, Edwards WD, Mohammed SF, Donovan JL, Roger VL, Grogan DR, et al. 
Abstract 17926: cardiac amyloid deposition is common in elderly patients with heart failure and preserved ejection fraction. Circulation 2010;122:A17926–A17926.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Abstract%2017926:%20cardiac%20amyloid%20deposition%20is%20common%20in%20elderly%20patients%20with%20heart%20failure%20and%20preserved%20ejection%20fraction&amp;volume=122&amp;publication_year=2010&amp;pages=A17926-A17926&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B4">
<span class="label">4.</span><cite>
Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. 
A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2017; 39:2799–2806.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehx589" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29048471/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=A%20new%20staging%20system%20for%20cardiac%20transthyretin%20amyloidosis&amp;volume=39&amp;publication_year=2017&amp;pages=2799-2806&amp;pmid=29048471&amp;doi=10.1093/eurheartj/ehx589&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B5">
<span class="label">5.</span><cite>
Cappelli F, Martone R, Gabriele M, Taborchi G, Morini S, Vignini E, et al. 
Biomarkers and prediction of prognosis in transthyretin-related cardiac amyloidosis: direct comparison of two staging systems. Can J Cardiol 2020;36:424–431.</cite> [<a href="https://doi.org/10.1016/j.cjca.2019.12.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32145869/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Can%20J%20Cardiol&amp;title=Biomarkers%20and%20prediction%20of%20prognosis%20in%20transthyretin-related%20cardiac%20amyloidosis:%20direct%20comparison%20of%20two%20staging%20systems&amp;volume=36&amp;publication_year=2020&amp;pages=424-431&amp;pmid=32145869&amp;doi=10.1016/j.cjca.2019.12.020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B6">
<span class="label">6.</span><cite>
Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. 
Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186–193.</cite> [<a href="https://doi.org/10.1161/01.CIR.0000152819.97857.9D" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15630027/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Cardiovascular%20magnetic%20resonance%20in%20cardiac%20amyloidosis&amp;volume=111&amp;publication_year=2005&amp;pages=186-193&amp;pmid=15630027&amp;doi=10.1161/01.CIR.0000152819.97857.9D&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B7">
<span class="label">7.</span><cite>
Gillmore Julian D, Maurer Mathew S, Falk Rodney H, Merlini G, Damy T, Dispenzieri A, et al. 
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404–2412.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.116.021612" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27143678/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Nonbiopsy%20diagnosis%20of%20cardiac%20transthyretin%20amyloidosis&amp;volume=133&amp;publication_year=2016&amp;pages=2404-2412&amp;pmid=27143678&amp;doi=10.1161/CIRCULATIONAHA.116.021612&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B8">
<span class="label">8.</span><cite>
Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, et al. 
Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076–1084.</cite> [<a href="https://doi.org/10.1016/j.jacc.2005.05.073" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16168294/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Noninvasive%20etiologic%20diagnosis%20of%20cardiac%20amyloidosis%20using%2099mTc-3,3-diphosphono-1,2-propanodicarboxylic%20acid%20scintigraphy&amp;volume=46&amp;publication_year=2005&amp;pages=1076-1084&amp;pmid=16168294&amp;doi=10.1016/j.jacc.2005.05.073&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B9">
<span class="label">9.</span><cite>
Rapezzi C, Guidalotti P, Salvi F, Riva L, Perugini E. Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. J Am Coll Cardiol 2008;51:1509–1510.</cite> [<a href="https://doi.org/10.1016/j.jacc.2007.12.038" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18402909/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Usefulness%20of%2099mTc-DPD%20scintigraphy%20in%20cardiac%20amyloidosis&amp;volume=51&amp;publication_year=2008&amp;pages=1509-1510&amp;pmid=18402909&amp;doi=10.1016/j.jacc.2007.12.038&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B10">
<span class="label">10.</span><cite>
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. 
Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007–1016.</cite> [<a href="https://doi.org/10.1056/NEJMoa1805689" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30145929/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Tafamidis%20treatment%20for%20patients%20with%20transthyretin%20amyloid%20cardiomyopathy&amp;volume=379&amp;publication_year=2018&amp;pages=1007-1016&amp;pmid=30145929&amp;doi=10.1056/NEJMoa1805689&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B11">
<span class="label">11.</span><cite>
Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, et al. 
Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019;139:431–443.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.118.035831" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12611557/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30586695/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Effects%20of%20patisiran,%20an%20RNA%20interference%20therapeutic,%20on%20cardiac%20parameters%20in%20patients%20with%20hereditary%20transthyretin-mediated%20amyloidosis&amp;volume=139&amp;publication_year=2019&amp;pages=431-443&amp;pmid=30586695&amp;doi=10.1161/CIRCULATIONAHA.118.035831&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B12">
<span class="label">12.</span><cite>
Dasgupta NR, Benson MD. Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, inotersen. Amyloid 2019;26:20–21.</cite> [<a href="https://doi.org/10.1080/13506129.2019.1582490" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31343363/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Treatment%20of%20ATTR%20cardiomyopathy%20with%20a%20TTR%20specific%20antisense%20oligonucleotide,%20inotersen&amp;volume=26&amp;publication_year=2019&amp;pages=20-21&amp;pmid=31343363&amp;doi=10.1080/13506129.2019.1582490&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B13">
<span class="label">13.</span><cite>
Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. 
Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 2019;140:16–26.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.118.038169" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31109193/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Natural%20history,%20quality%20of%20life,%20and%20outcome%20in%20cardiac%20transthyretin%20amyloidosis&amp;volume=140&amp;publication_year=2019&amp;pages=16-26&amp;pmid=31109193&amp;doi=10.1161/CIRCULATIONAHA.118.038169&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B14">
<span class="label">14.</span><cite>
Galat A, Van der Gucht A, Guellich A, Bodez D, Cottereau A-S, Guendouz S, et al. 
Early phase 99Tc-HMDP scintigraphy for the diagnosis and typing of cardiac amyloidosis. JACC Cardiovasc Imaging 2017;10:601–603.</cite> [<a href="https://doi.org/10.1016/j.jcmg.2016.05.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27424245/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JACC%20Cardiovasc%20Imaging&amp;title=Early%20phase%2099Tc-HMDP%20scintigraphy%20for%20the%20diagnosis%20and%20typing%20of%20cardiac%20amyloidosis&amp;volume=10&amp;publication_year=2017&amp;pages=601-603&amp;pmid=27424245&amp;doi=10.1016/j.jcmg.2016.05.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B15">
<span class="label">15.</span><cite>
Puchtler H, Sweat F, Levine M. On the binging of congo red by amyloid. J Histochem Cytochem 1962;10:355–364.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Histochem%20Cytochem&amp;title=On%20the%20binging%20of%20congo%20red%20by%20amyloid&amp;volume=10&amp;publication_year=1962&amp;pages=355-364&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B16">
<span class="label">16.</span><cite>
Gilbertson JA, Hunt T, Hawkins PN. Amyloid typing: experience from a large referral centre. In: Picken PFMM, Dogan MDPDA, Herrera MDGA, eds. Amyloid and related disorders: surgical pathology and clinical correlations. Totowa, NJ: Humana Press; 2012, p231–238.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Amyloid%20and%20related%20disorders:%20surgical%20pathology%20and%20clinical%20correlations&amp;publication_year=2012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B17">
<span class="label">17.</span><cite>
Rezk T, Gilbertson JA, Mangione PP, Rowczenio D, Rendell NB, Canetti D, et al. 
The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. J Pathol Clin Res 2019;5:145–153.</cite> [<a href="https://doi.org/10.1002/cjp2.126" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6648380/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30740936/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Pathol%20Clin%20Res&amp;title=The%20complementary%20role%20of%20histology%20and%20proteomics%20for%20diagnosis%20and%20typing%20of%20systemic%20amyloidosis&amp;volume=5&amp;publication_year=2019&amp;pages=145-153&amp;pmid=30740936&amp;doi=10.1002/cjp2.126&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B18">
<span class="label">18.</span><cite>
Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, et al. 
Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat 2014;35:E2403–E2412.</cite> [<a href="https://doi.org/10.1002/humu.22619" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25044787/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hum%20Mutat&amp;title=Online%20registry%20for%20mutations%20in%20hereditary%20amyloidosis%20including%20nomenclature%20recommendations&amp;volume=35&amp;publication_year=2014&amp;pages=E2403-E2412&amp;pmid=25044787&amp;doi=10.1002/humu.22619&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B19">
<span class="label">19.</span><cite>
Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. 
Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016;68:1014–1020.</cite> [<a href="https://doi.org/10.1016/j.jacc.2016.06.033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27585505/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Natural%20history%20of%20wild-type%20transthyretin%20cardiac%20amyloidosis%20and%20risk%20stratification%20using%20a%20novel%20staging%20system&amp;volume=68&amp;publication_year=2016&amp;pages=1014-1020&amp;pmid=27585505&amp;doi=10.1016/j.jacc.2016.06.033&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B20">
<span class="label">20.</span><cite>
Cheng RK, Levy WC, Vasbinder A, Teruya S, De Los Santos J, Leedy D, et al. 
Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis. JACC CardioOncol 2020;2:414–424.</cite> [<a href="https://doi.org/10.1016/j.jaccao.2020.06.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7561022/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33073249/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JACC%20CardioOncol&amp;title=Diuretic%20dose%20and%20NYHA%20functional%20class%20are%20independent%20predictors%20of%20mortality%20in%20patients%20with%20transthyretin%20cardiac%20amyloidosis&amp;volume=2&amp;publication_year=2020&amp;pages=414-424&amp;pmid=33073249&amp;doi=10.1016/j.jaccao.2020.06.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B21">
<span class="label">21.</span><cite>
Gillmore JD, Garcia-Pavia P, Grogan M, Hanna MA, Heitner SB, Jacoby D, et al. 
ATTRibute-CM: A randomized, double-blind, placebo-controlled, multi-center, Global phase 3 study of AG10 in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) [abstract]. Circulation 2019;140:A14214.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=ATTRibute-CM:%20A%20randomized,%20double-blind,%20placebo-controlled,%20multi-center,%20Global%20phase%203%20study%20of%20AG10%20in%20patients%20with%20transthyretin%20amyloid%20cardiomyopathy%20(ATTR-CM)%20%5Babstract%5D&amp;volume=140&amp;publication_year=2019&amp;pages=A14214&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B22">
<span class="label">22.</span><cite>
ClinicalTrials.gov . APOLLO-B: a study to evaluate Patisiran in participants with transthyretin amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy). Available from: <a href="https://www.clinicaltrials.gov/ct2/show/NCT03997383" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.clinicaltrials.gov/ct2/show/NCT03997383</a> (accessed 02 Jan 2022).</cite>
</li>
<li id="ehac259-B23">
<span class="label">23.</span><cite>
ClinicalTrials.gov . HELIOS-B: a study to evaluate Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. Available from: <a href="https://clinicaltrials.gov/ct2/show/NCT04153149" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/ct2/show/NCT04153149</a> (accessed 02 Jan 2022).</cite>
</li>
<li id="ehac259-B24">
<span class="label">24.</span><cite>
Royston P. Explained variation for survival models. Stata J 2006;6:83–96.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Stata%20J&amp;title=Explained%20variation%20for%20survival%20models&amp;volume=6&amp;publication_year=2006&amp;pages=83-96&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B25">
<span class="label">25.</span><cite>
Davis RC, Hobbs FDR, Kenkre JE, Roalfe AK, Iles R, Lip GYH, et al. 
Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace 2012;14:1553–1559.</cite> [<a href="https://doi.org/10.1093/europace/eus087" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22490371/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Europace&amp;title=Prevalence%20of%20atrial%20fibrillation%20in%20the%20general%20population%20and%20in%20high-risk%20groups:%20the%20ECHOES%20study&amp;volume=14&amp;publication_year=2012&amp;pages=1553-1559&amp;pmid=22490371&amp;doi=10.1093/europace/eus087&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B26">
<span class="label">26.</span><cite>
Bradshaw PJ, Stobie P, Knuiman MW, Briffa TG, Hobbs MS. Trends in the incidence and prevalence of cardiac pacemaker insertions in an ageing population. Open Heart 2014;1:e000177.</cite> [<a href="https://doi.org/10.1136/openhrt-2014-000177" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4265147/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25512875/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Open%20Heart&amp;title=Trends%20in%20the%20incidence%20and%20prevalence%20of%20cardiac%20pacemaker%20insertions%20in%20an%20ageing%20population&amp;volume=1&amp;publication_year=2014&amp;pages=e000177&amp;pmid=25512875&amp;doi=10.1136/openhrt-2014-000177&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B27">
<span class="label">27.</span><cite>
Zhou B, Danaei G, Stevens GA, Bixby H, Taddei C, Carrillo-Larco RM, et al. 
Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet 2019;394:639–651.</cite> [<a href="https://doi.org/10.1016/S0140-6736(19)31145-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6717084/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31327564/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Long-term%20and%20recent%20trends%20in%20hypertension%20awareness,%20treatment,%20and%20control%20in%2012%20high-income%20countries:%20an%20analysis%20of%20123%20nationally%20representative%20surveys&amp;volume=394&amp;publication_year=2019&amp;pages=639-651&amp;pmid=31327564&amp;doi=10.1016/S0140-6736(19)31145-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B28">
<span class="label">28.</span><cite>
Health Survey for England 2017 Cardiovascular diseases . Available from: <a href="http://healthsurvey.hscic.gov.uk/media/78646/HSE17-CVD-rep.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://healthsurvey.hscic.gov.uk/media/78646/HSE17-CVD-rep.pdf</a> (accessed 02 Jan 2022).</cite>
</li>
<li id="ehac259-B29">
<span class="label">29.</span><cite>
Diabetes in the UK 2010: key statistics on diabetes. Available from: <a href="https://www.diabetes.org.uk/resources-s3/2017-11/diabetes_in_the_uk_2010.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.diabetes.org.uk/resources-s3/2017-11/diabetes_in_the_uk_2010.pdf</a> (accessed 02 Jan 2022).</cite>
</li>
<li id="ehac259-B30">
<span class="label">30.</span><cite>
Atroshi I, Gummesson C, Johnsson R, Ornstein E, Ranstam J, Rosén I. Prevalence of carpal tunnel syndrome in a general population. JAMA 1999;282:153–158.</cite> [<a href="https://doi.org/10.1001/jama.282.2.153" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10411196/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Prevalence%20of%20carpal%20tunnel%20syndrome%20in%20a%20general%20population&amp;volume=282&amp;publication_year=1999&amp;pages=153-158&amp;pmid=10411196&amp;doi=10.1001/jama.282.2.153&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ehac259-B31">
<span class="label">31.</span><cite>
BridgeBio . <em>Month 12 topline results from phase 3 ATTRibute-CM study</em>. 2021. <a href="https://bridgebio.com/news/bridgebio-pharma-reports-month-12-topline-results-from-phase-3-attribute-cm-study/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://bridgebio.com/news/bridgebio-pharma-reports-month-12-topline-results-from-phase-3-attribute-cm-study/</a> (16 May 2022, date last accessed).</cite>
</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>ehac259_Supplementary_Data</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/9279112/bin/ehac259_supplementary_data.docx" data-ga-action="click_feat_suppl" class="usa-link">Click here for additional data file.</a><sup> (17.7KB, docx) </sup>
</div></div></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from European Heart Journal are provided here courtesy of <strong>Oxford University Press</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1093/eurheartj/ehac259"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/ehac259.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.3 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/9279112/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/9279112/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC9279112%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC9279112/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC9279112/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC9279112/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/35608040/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC9279112/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/35608040/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC9279112/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/9279112/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="djVqoLA3iDtMjx6UGSPN6wrw2fmYnh0ae2I7RwYffZIiD0pfU6UtUaT6N3Cy0RHO">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
